ENTX - Company ID 0001638097
The table below shows Entera Bio Ltd.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.37M | -$6.82M | -$7.31M | -$12.50M | -$9.06M | -$10.56M |
| Capital expenditure | $107.00K | $3.00K | $17.00K | $47.00K | $17.00K | $53.00K |
| Investing cash flow | -$107.00K | -$3.00K | -$17.00K | -$102.00K | -$17.00K | -$53.00K |
| Dividends paid | - | - | - | - |
Entera Bio Ltd. reported operating cash flow of -$7.37M for fiscal year 2025. That is down 8.1% from -$6.82M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow grew from -$10.56M (FY 2020) to -$7.37M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $13.71M | $4.48M | $6.04M | $13.00K | $25.38M | $4.05M |